Organization

Hoffmann-La Roche

1 member

Corporate ratings

High Risk

Roche is rated High Risk because it scores poorly across all measured categories, including cancellations, discriminatory philanthropy, employment practices, and political advocacy and funding activities. The company is characterized as prioritizing identity-based and partisan initiatives over merit-based business practices, which the report views as undermining free speech, free exercise, and free enterprise.

CancellationsHigh Risk
Discriminatory PhilanthropyHigh Risk
Employment ProtectionHigh Risk
Advocacy BiasHigh Risk
FundingHigh Risk
Political ActionsHigh Risk

Assessment by . Summary generated by IJR from their published rating.

In the news

Photo: Goleisureintl / Wikimedia Commons (CC BY 4.0)

Health

Roche cobas BV/CV vaginitis test FDA-cleared

Roche has received FDA 510(k) clearance for the cobas BV/CV assay, which detects bacterial vaginosis and Candida vaginitis from a single vaginal swab using real-time PCR, promising more accurate diagnoses than traditional methods. The test can be run on the cobas platform alongside other sexual-health assays and is intended for professional laboratory use, aiming to reduce misdiagnosis and speed appropriate treatment.

6 sources

Hoffmann-La Roche

Corporate ratings

In the news

Roche cobas BV/CV vaginitis test FDA-cleared

Articleresearching the web…

Hoffmann-La Roche

Corporate ratings

In the news

Roche cobas BV/CV vaginitis test FDA-cleared

Articleresearching the web…